Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2009, to April 30, 2010. The report, dated May 10, 2010, serves as a Block Listing Six Monthly Return detailing the status of various employee share option schemes. It does not contain general business operations updates or financial performance data.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting the number of securities allotted and the remaining balance of unallotted securities under specific share option plans.
Material Changes in Share Option Schemes
The following changes occurred in the unallotted securities balances between the previous return and the end of the period (April 30, 2010):
- GlaxoSmithKline Share Option Plan - Ordinary Shares: Decreased by 1,831,905 shares (issued/allotted), leaving a balance of 3,195,611.
- GlaxoSmithKline Share Option Plan - ADS: Decreased by 841,634 shares (issued/allotted), leaving a balance of 5,184,142.
- GlaxoSmithKline Savings Related Share Option Scheme: Decreased by 731,368 shares (issued/allotted), leaving a balance of 4,459,878.
- Other Schemes: No securities were issued or allotted during the period for the Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, and SmithKline Beecham 1989 plans. Their balances remained unchanged from the previous return.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a regulatory compliance report regarding equity compensation plans.
Important Facts for Investors to Verify
- Total of 3,404,907 shares were issued or allotted across three active schemes during the six-month period.
- Approximately 32.8 million shares remain unallotted across all reported schemes as of April 30, 2010.
- No increases were applied for in any of the block schemes during this reporting period.
- Investors should refer to the company's Form 20-F or quarterly earnings releases for financial performance metrics, as they are absent from this filing.